Marinus Pharma (NASDAQ: MRNS) reported Q2 EPS of ($0.61), $0.11 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $6.08 million versus the consensus estimate of $5.71 million.

For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.